Major histocompatibility class II (MHC-II) expression is critical for immune responses and is controlled by the MHC-II transactivator CIITA. CIITA is primarily regulated at the transcriptional level and is expressed from three main promoters with myeloid, lymphoid and interferon (IFN)-γ-treated non-hematopoietic cells using promoters pI, pIII and pIV, respectively. Recent studies in nonhematopoietic cells suggest that a series of distal regulatory elements may be involved in regulating CIITA transcription. To identify distal elements in B cells, a DNase I hypersensitivity screen was performed, revealing a series of potential novel regulatory elements. These elements were analyzed computationally and biochemically. Several regions displayed active histone modifications and/or enhanced expression of a reporter gene. Four of the elements interacted with pIII in B cells. These same four regions were also found to interact with pI in splenic dendritic cells (spDC). Intriguingly, examination of the above interactions in pI-knockout-derived spDC showed a switch to the next available promoter, pIII. Extensive DNA methylation was found at the pI region in B cells, suggesting that this promoter is not accessible in B cells. Thus, CIITA expression is likely mediated in hematopoietic cells by common elements with promoter accessibility having a part in promoter choice.
INTRODUCTION
Major histocompatibility class II (MHC-II) genes are essential for antigen presentation. MHC-II proteins form heterodimers that are expressed principally on the surface of antigen-presenting cells, such as B cells, macrophages and dendritic cells, but are interferon (IFN)γ-inducible in most non-immune cells. [1] [2] [3] MHC-II proteins present peptide antigens to CD4+ helper T cells, 4 which upon recognition of their cognate antigen, become activated, triggering a complex immune response. Using the same MHC-II peptide/ T-cell receptor interaction, activated CD4+ T cells stimulate antigen-specific B-cell differentiation to antibody-secreting plasma cells, thereby generating antigen-specific humoral immune responses. MHC-II expression is highly regulated at the level of transcription. The transcription factors RFX, CREB and NF-Y are necessary but not sufficient for MHC-II expression (reviewed in Choi et al. 5 ). The MHC-II transactivator, CIITA, is required to interact with these factors and the basal transcription machinery to initiate MHC-II expression. 6 Unlike RFX, CREB and NF-Y, which are ubiquitously expressed, CIITA expression is limiting. Thus, CIITA and the mechanisms that control its expression are responsible for regulating MHC-II gene expression and antigen processing.
CIITA is regulated primarily at the level of transcription. 7 CIITA is transcribed from three main promoters, which are used principally in a cell-type-dependent manner. Each promoter encodes a unique first exon that is spliced into a common second exon to create distinct isoforms of CIITA. 8 Cells of the myeloid lineage, including splenic-derived dendritic cells (spDC), primarily express CIITA from the most distal promoter (promoter I or pI). 8 Cells of the lymphoid lineage principally express CIITA from promoter III (pIII), and most cell types, including non-hematopoietic cells, will use promoter IV (pIV) in an IFNγ-inducible manner. 2, [8] [9] [10] [11] Individual roles for these isoforms are unclear; however, they appear to be somewhat interchangeable. 12 When CIITA is dysregulated or absent, a variety of immune defects are observed. CIITA was first identified in a study to discover the underlying gene responsible for one complementation group of bare lymphocyte syndrome, a severe combined immune deficiency disease. 13 CIITA knockout (KO) mice lack positive selection for CD4+ T cells and do not respond well to immunization or pathogenic challenge.
14 Thus, appropriate regulation of CIITA is key to healthy immune responses.
The proximal regulatory region for pIII is well defined. A minimal unit necessary for maximal expression is contained within 319 bp of the transcription start site that contains multiple cis-regulatory elements: ARE-1 and ARE-2 elements, a nuclear factor-1-binding site termed site A, site B and site C, 15 as well as binding sites for AP1 9 Sp1 16 acute myeloid leukemia 2, CREB 17 and the repressors PRDI-BF1/BLIMP-1 18, 19 and ZBTB32. 20 PU.1, an essential B-cell transcription factor, was also found to be important for positive regulation of CIITA pIII through site C, working in conjunction with E47 and IRF-4. 21 In contrast to its well-defined proximal regulatory elements, only one distal regulatory element for pIII was identified previously and termed hypersensitive site 1 (HSS1). 22 HSS1 is located~3 kb upstream of pI. PU.1-bound HSS1 was shown to interact directly with pIII. 22 HeLa cells, which can induce CIITA pIV expression in response to IFNγ, were found to use a network of distal elements located both upstream and downstream of the CIITA promoter regions and gene. 23 However, it is not known whether other elements regulate CIITA expression in lymphocytes or in myeloid cell types.
To identify novel elements regulating CIITA in B cells, a PCRbased DNase I hypersensitivity assay was used and identified a number of potential regulatory regions. Four of these distal regions were found to interact with pIII in B cells using a chromatin conformation capture (3C) assay. The most 3′ of these elements was found to bind the transcriptional insulator CCCTCbinding factor (CTCF). One of the 5′ elements identified was HSS1, whereas the two others were novel to B cells. These two sites were able to activate a heterologous promoter, and one displayed common histone marks of active chromatin/enhancers, as well as PU.1 binding. All four of the interacting regions were also able to interact with pI in spDC. Interactions between all distal regulatory elements and CIITA pI were reconfigured to pIII in spDC derived from mice containing a genetic deletion of pI. This rearrangement of promoter choice suggested that these elements search for an accessible promoter region to drive transcription. In B cells, the pI promoter contains extensive DNA methylation and is likely to be in an epigenetic restricted state, with pIII representing the first available promoter. Thus, CIITA's regulatory regions function across hematopoietic lineages and demonstrate flexibility in choosing promoters to drive CIITA expression.
RESULTS
Multiple DNase I-hypersensitive sites are present in the CIITA locus in murine B cells To identify regulatory regions within the CIITA locus, a PCR-based DNase I hypersensitivity assay was performed in the murine B-cell line BCL1 (CIITA-expressing). Comparisons with the CIITA nonexpressing plasma cell line P3X were carried out such that B lymphocyte-specific elements might be identified. In these assays a series of 95 amplicons (1-2 kb in length) were designed to span the entire CIITA gene and the surrounding regions and encompassed~160 kb of DNA (Figure 1a ). Regions encoding repetitive DNA sequences were not screened, as it would not be possible to map any activity to the CIITA locus. Noncoding regions highly conserved between mice and humans were preferentially included as these might have regulatory function (Figure 1a) . Cell lysates were incubated with increasing concentrations of DNase I, DNA-purified and used as a substrate for PCR. Analysis of the band intensities of the PCR amplicons on ethidium bromide-stained gels was used to determine a slope of sensitivity (Figures 1b and c) .
The absolute values of the negative slopes were plotted along the sequence (Figure 1a) . Amplicons that showed no change in intensity with increasing DNase I treatments were not examined further. Regions of interest (ROIs) that displayed a decrease in amplicon intensity, corresponding to a substantial decrease in slope in BCL1 cells (for example, regions − 3, +10 and +15 kb from the pI transcription start site (TSS)) were considered as potential regulatory regions for CIITA (Figure 1b ). To choose regions for additional study, sequence conservation with humans was examined, and only regions with mouse/human sequence homology were considered further. From these analyses, 13 regions were chosen ( Figure 1a , horizontal bars).
To provide a higher-resolution analysis for the DNase I-hypersensitive sites, quantitative PCR (qPCR) using smaller amplicon Nubp1  pI  pIII  pIV  HSS1   -10  -20  -30  -40  +10  -50  -70kb  0  +20  +30  +40  +50  -60   Clec16a   +60  +70  +80 Figure 1 . Analysis of DNase I hypersensitivity across the CIITA locus reveals 13 regions of interest. (a) A schematic of the CIITA locus is shown along with vertebrate and human conservation downloaded from the UCSC Genome Browser. 51 The 95 amplicons across the CIITA locus used to screen non-repetitive regions for DNase I hypersensitivity using conventional PCR are displayed as black bars. Horizontal black lines indicate regions of interest chosen for further analysis. The relative hypersensitivity plot (bottom) derived from data shown in Supplementary  Figure 1 displays the absolute value of slopes for each amplicon in both BCL1 (outlined bars) and P3X cells (gray shadow bars). subsets that could be evaluated using real-time PCR was employed. As above, BCL1 and P3X cell lysates were subjected to increasing concentrations of DNase I. For analysis, amplicons of 200-600 bp in length were designed within each of the ROIs from the low-resolution screen (Figure 2a ). Where possible, multiple amplicons were used for a single region. At this resolution, BCL1 cells were more accessible to DNase I than P3X at the CIITA locus (Figure 2b ). The results of this analysis identified eight regions of hypersensitivity (−47, − 15, − 3, +10, +11, +15, +36 and +37 kb from the TSS) for further investigation, with all being more hypersensitive in BCL1 than P3X.
Four ROIs physically interact with pIII when CIITA is expressed One mechanism through which regulatory regions exhibit activity is via physical interactions with their cognate promoters. To determine whether any ROIs were exhibiting regulatory activity by physically interacting with the lymphocyte-specific promoter (pIII), 3C assays [24] [25] [26] were performed. For these experiments,~138 kb of the CIITA locus was queried, and included nearly all hypersensitive regions identified above irrespective of whether the region was hypersensitive only in BCL1 cells or was also hypersensitive in P3X cells. In addition, regions that were found to be enriched for H3K4me1 in B cells 27 were analyzed. Primary splenic B cells, which principally use pIII, were used for this analysis (Figure 3a) . To improve resolution and to verify interactions, two different restriction enzymes were chosen for 3C analysis (Figure 3b ). HindIII restriction digestion separates all the CIITA promoters from one another, and EcoRI restriction digestion refines the location of interacting regions and verifies the interactions observed in the HindIII system. The map of interactions revealed that there were three main regions that strongly interacted with pIII in splenic B cells (Figure 3c ). These included regions within restriction fragments H5 and E4, which encompassed the − 15 ROI; H6 and E6; and H16 and E12. Under the conditions used, interactions between pIII and HSS1 22 were not detected. Detection of pIII and HSS1 interactions previously were obtained using a more sensitive 3C assay that employed a higher concentration of formaldehyde in addition to a longer crosslinking time (15 min) than used above. To determine whether such crosslinking could be replicated, 3C was repeated for the HSS1 region (H7), along with control region H4 and additional ROIs in H5 and H16. As observed, under these conditions, interactions with H7 were detected with no increase in background interactions with H4 or increased interactions at H5 and H16 (Figure 3d ). Together, these data suggest that in addition to the previously identified HSS1 three new regions interact with pIII to potentially regulate CIITA expression.
CTCF binds at multiple locations across the CIITA locus In silico sequence analyses of the H16/E12-interacting fragment suggested that CTCF might bind this region. CTCF is a transcriptional-insulator-binding protein that can block the effects of a downstream enhancer from acting on a gene promoter. 28 CTCF is also known to have an important role in creating a threedimensional (3D) architecture involved in gene regulation. 26 Analysis of CTCF chromatin immunoprecipitation (ChIP)-seq data for B cells and plasmablasts 29 across the locus identified six CTCF sites ( Figure 4a ). Whereas two sets of these sites were in genes upstream of CIITA (Nubp1) and downstream (Clec16a), the other four were intragenic, with two of the sites (+40 and +43) residing in H16/E12. To confirm the ChIP-seq analysis, real-time coupled ChIP was performed on these regions and compared with a positive control for the H19 locus and a negative control located at +44.5 in the CIITA locus in BCL1 and P3X cells. The results confirmed CTCF occupancy at the +23, +38, +40 and +43 kb sites ( Figure 4b ). CTCF occupancy at +23 and +38 was increased significantly in BCL1 cells as compared with P3X plasma cells.
CIITA-hypersensitive sites are associated with active histone modifications As regulatory regions commonly contain distinct histone modifications associated with open chromatin or enhancers, eight ROIs, the three promoters and three negative control sequences were assessed for the chromatin marks H3K4me1, H3K9Ac and H3K27ac in both BCL1 and P3X cells ( Figure 5 ). H3K4me1 is associated with enhancer regions 30 and when coupled with H3K27Ac is indicative of active enhancers. 31 H3K9Ac is often found at active promoters and regulatory regions. 32 For the most part, active modifications were found at many of the ROIs in BCL1 cells and these marks were reduced in P3X cells (Figure 5a ). Major peaks of H3K9ac and H3K27ac modifications were found at pIII and pIV, as well as within the body of the gene at the +15 and +36 ROIs. Although H3K9ac was not found at any of the ROIs upstream of CIITA, it was found at each of the promoters and at the +11, +15, +36 and +37 ROIs. H3K27ac was weakly present at some of the upstream regions, including the − 15 and − 3 (HSS1) ROIs, but was mostly restricted to the same downstream regions as H3K9ac. H3K4me1 was present at pIII and pIV, and within the gene body, and at all of the above ROIs, including the upstream ROIs − 3 and − 15. Intriguingly, the presence of H3K4me1 at the − 15 ROI and at pIV were similar between the BCL1 and P3X cells, suggesting that these regions may be in an open/accessible state, even though CIITA is not expressed in P3X cells.
Comparison of these data with publically available ChIP-seq data sets in primary murine B cells 27, 33 showed concordance of peaks of H3K9ac at HSS1, pIII and pIV promoter regions and lower levels across the body of the CIITA gene ( Figure 5 ). H3K4me3, which signifies active or RNA Pol II-engaged promoters, was found only at pIII and pIV (Figure 5b ).
PU.1 binds to many regions across the CIITA locus The transcription factor PU.1 is known to be involved in regulation of CIITA from pIII. 22 Analysis of the available ChIP-seq data set for PU.1 (Figure 5b ) showed enrichment at five regions around the CIITA gene, including pIII, and coincided with peaks of DNase I hypersensitivity. 27, 34 Overall, these data indicate a potential regulatory role for four regions: − 3 (HSS1), +11, +15 and +36 ROIs. mice were assayed for CIITA promoter usage. Three independent RNA samples were examined using qRT-PCR to query isoform-specific CIITA expression and were normalized to 18S RNA levels. Experimental variability is represented by s.e.m. (b) Schematic of the CIITA locus showing 3C fragments queried as well as HindIII and EcoRI restriction sites. Arrows indicate 3C primers used to query fragments and vertical lines represent restriction sites. Gray arrows indicate the anchor primer for the pIII fragment. (c) 3C was performed using three independent isolations of primary splenic B cells, and the relative crosslinking frequency with the anchor fragment as determined by the 3C assay is shown using HindIII or EcoRI as the restriction enzyme. (d) In order to detect the lower-frequency interaction with the HSS1-containing fragment, a 15-min crosslinking time with 2% formaldehyde was used in the 3C assay as previously reported. 22 Error bars represent the s.d. across three independent replicates and *Po 0.05. 27, 33 and DNase I data (CD43-and A20 B cells) 34 plotted with respect to the eight ROIs (black), three CIITA promoters (magenta) and three negative control sequences (orange). 27 to be enriched for PU.1 binding (−4, +16, +19 and +35), as well as several found through ChIP analysis (Figure 5a ) to be enriched for marks of active enhancers (+36 and +37), were also examined in this context. These constructs were transfected into A20 cells and assayed for expression of the reporter. Intriguingly, only three of the constructs were able to augment the reporter and included the 3C -interacting regions H5/E4 at the − 15 ROI, H5/E6 at − 8.2 and within the +35 PU.1-binding site ( Figure 6 ). Thus, three regions display the ability to enhance the expression of a heterologous reporter gene construct. The other regions were unable to function independently.
Interacting regions are shared between B cells and spDC Given the potential for the ROIs that interact with pIII to have some role in CIITA expression from pI, the 3C chromatin architecture of the CIITA locus was examined in dendritic cells. spDC, which principally use pI (Figure 7a ), were isolated from wildtype C57BL/6 mice and 3C was performed using HindIII as the restriction enzyme. 3C analysis revealed that in wild-type spDC, restriction fragments H5, H6, H7 and H16 interact with pI (Figures 7b and c) . Thus, the same ROIs that interact with pIII in B cells interact with pI in spDC.
A mouse (pI-KO) carrying a deletion of the pI promoter region, including~300 bp upstream and 100 bp downstream of the TSS, was created and analyzed previously. 12 spDC from these mice expressed near wild-type levels of CIITA mRNA that initiated from pIII (reviewed in Zinzow-Kramer et al. 12 and Figure 7a ), suggesting the possibility that promoter interactions would simply shift from pI to pIII. To test this, 3C was performed on spDC isolated from these mice. Indeed, in pI-KO spDC, the interacting restriction fragments containing the active ROI regulatory elements shifted their interactions to the next available promoter, pIII (Figure 7b) . Together, these data imply that four of the elements are commonly used to regulate CIITA in B cells and dendritic cells.
The proximal promoter region of pI in spDC and B cells has altered methylation that correlates with promoter use The finding that common elements were interacting with the active promoter suggested that there may be another mechanism that helps to govern promoter use. One hypothesis is that an epigenetic mechanism, such as DNA methylation contributes to CIITA promoter choice. Thus, clonal bisulfite sequencing 35 was performed to determine the methylation status of promoter proximal CpGs within the three CIITA promoters (Figure 8a ). spDC and B cells were used as DNA sources. The results showed that the pI promoter region was differentially methylated (Figures 8b and  c) . The three most 5′ CpGs (−95, − 69 and +38 bp) surrounding the pI TSS were unmethylated in spDC but almost completely methylated in B cells. The four downstream pI CpGs showed variable methylation in spDC and again were nearly completely methylated in B cells. In sharp contrast, pIII and pIV showed low to almost no methylation in spDC and B cells. These data suggest that the ability to use pI in B cells may be compromised by the presence of CpG methylation at that promoter.
DISCUSSION
Despite its importance in controlling MHC-II gene expression and antigen presentation, distal cis-acting elements regulating CIITA gene expression in B cells or dendritic cells have not been extensively studied and are poorly defined in both the human and mouse systems. To develop an understanding of the complexity and number of CIITA distal regulatory elements, DNase I hypersensitivity, 3C and ChIP for the determination of active histone modifications were employed. Combining the results from these assays with ChIP-seq data sets 27, 29, 33, 34, 36 and mammalian sequence conservation analyses provided a total of 21 elements as potential candidates for regulating CIITA gene expression. However, as discussed below, clear regulatory potential as defined by 3C interactions with the promoter and/or gene reporter assays was observed for only four of these elements. This suggests that some of the features that led to an element's inclusion in the analyses may be a consequence of transcription or participation in the architectural structure of the locus but may not have a direct or major role in the transcriptional regulation of CIITA. In addition, these assays identified four CTCF sites that may contribute to the organization of the locus. DNase I-hypersensitive regions, which are often associated with enhancers and promoter regions, provided a first pass of potential regions that were accessible in B cells but not plasma cells and could reveal elements required for B-cell expression of CIITA. Several regions were also hypersensitive in both B cells and plasma cells, suggesting that they may be performing roles associated with the architectural features of the locus, such as the CTCF sites discussed below. Three ENCODE DNase I tracks for B cells (CD43 − B cells; CD19+ B cells and A20 lymphoma cells) were available 34 for analysis. Examination of these tracks with the regions identified in this study showed congruence at three of the Figure 3b . The relative crosslinking frequency with the indicated anchor fragments as determined with the 3C assay is shown for WT and pI-KO spDC. These experiments were performed three times. Error bars indicate s.d., and *Po 0.05 as determined by a one-tailed Student's t-test.
DNase I sites (+15, +36 and +37), two at PU.1 sites (+16 and +19) and two at CTCF-binding sites (+40 and +43). The promoter regions at pIII and pIV were also hypersensitive in the DNase I tracks. On the upstream side of pIII, only one strong DNase I peak appeared in A20 cells but not within the primary B-cell populations. This broad region encompassed HSS1, which was previously identified. 22 Thus, no hypersensitivity was revealed for − 15 and − 8.2 in B cells through the global genome-wide DNase I assays. This may reflect the sensitivity associated with qPCR or biases reflected in high-throughput sequencing. 37, 38 Alternatively, differences in DNase I hypersensitivity may reflect inherent differences between primary B cells, BCL1 and A20 tumor cell lines used in this study and the various analyses discussed above.
Long-distance regulatory regions are now thought to function through looping interactions with promoters or other elements. 26, [39] [40] [41] This looping can be mediated by transcription factors, as described at the MCP-1 locus between an upstream NF-κB element and the downstream Sp1 promoter regulatory element 42 or via the chromosomal organizing factor CTCF as shown at the human and mouse MHC-II loci. 26, 29 To identify regions that would interact with pIII and potentially regulate transcription, 3C was performed for 490% of the restriction fragments covering 138 kb of the CIITA locus. The use of two restriction enzymes in the 3C assay increased the ability to separate potential interacting elements from each other, as well as provided an independent confirmation for any observed interaction. Although the 3C analysis in this study was promoter-centric, three very strong interactions (−15, − 8.2 and +40/+43) with pIII were observed, and these interactions highlight the power of this approach. A fourth interaction with HSS1 and pIII, which was previously reported, 22 was recapitulated. These interactions are summarized in Figure 9 . CTCF was bound at the +40/+43 3C -interacting region in not only B cells and plasmablasts but also most cell and tissue types examined in the ENCODE project (Supplementary Table 1 ; reviewed in Bernstein et al. 34 ). The conservation of CTCF binding to this region among cell types and its independence with respect to CIITA gene expression suggest that this site may function as the 3′ boundary for CIITA regulatory elements but not regulate the gene directly. This statement is further supported by experiments in which short interfering RNA depletion of CTCF did not affect CIITA mRNA levels in B cells 26, 29 and the observation that this region of the genome is dense, with two genes immediately 3′ to CIITA. Such boundaries may function to restrict the activity of the gene-specific enhancers in the region.
Identification of histone marks of open chromatin and active enhancers serve as useful tools for recognition of putative enhancer elements. Six of the ROIs fit with the typical profile of an enhancer element being marked by H3K4me1, 30 H3K27Ac, 31 and H3K9Ac. 32 The presence of these chromatin marks indicates that there are potentially a number of intragenic enhancer elements inside of the CIITA gene itself (+11, +15 and +36). However, when 1-kb segments surrounding these ROIs were cloned into a luciferase expression vector, these regions showed no enhancer activity (data not shown). Whereas this could be a result of a lack of true enhancer activity, it is also possible that these large fragments also contained repressive elements in pI  pIII  pIV   100bp   -95  -69  +38  +142  +184  +235  +320  -446  -414  -406  -377  -115  -89  -265  -148  -50  -4  +18  +27  +64  +81  +83  +114  +136  +165  +184  +237   1  7 8  13  27 CpG  14   1  71  7  8  1 3 8  1 3  27  14  27  14   1  7  8  1 3  27 addition to the putative enhancers. It is also possible that these elements only work in concert with the other elements. In contrast, the − 15 ROI displayed positive regulatory activity in the luciferase assay, supporting the case for its role as an active enhancer. The − 15 site is conserved between mouse and human, and is homologous to a region involved in IFNγ-inducible CIITA expression from pIV in HeLa cells. 23 The +40 CTCF-binding region was also conserved in humans and participated in IFNγ-mediated CIITA expression through pIV. 23 In contrast, the − 8.2 site, which displayed regulatory activity and interacted with pI and pIII, did not possess any typical histone modifications of active enhancers. The lack of H3K4me1, H3K27Ac and H3K9Ac does not preclude the possibility of an active regulatory element as there may be yet undetermined modifications/activities at this region. [43] [44] [45] [46] The − 8.2 site may therefore fall under a unique classification of cis-elements that do not fit the typical active enhancer model. In addition, the +11, +15 and +35/ +36 sites appear to be marked as active enhancers, as well as having PU.1 bound, but do not physically interact with the promoter or display regulatory activity, suggesting supporting roles for these regions, or designating the observed histone modification activities as a consequence of transcription through them. Alternatively, they may simply function to maintain an open chromatin state for transcription through the gene.
The − 3 site (HSS1) was previously shown to be involved in regulating CIITA expression from pIII in B cells. 22 It was found in this study to be marked with active enhancer marks, as well as verifying previous data showing PU.1 binding at this site. As PU.1 has been previously shown to mediate looping at the CIITA locus 22 and binds at two of the four promoter-interacting restriction fragments, this is the most likely candidate for mediating the complex 3D architecture of the locus. PU.1 is highly expressed in cells of the myeloid lineage 30 and was also shown to have a role in CIITA expression from pI in dendritic cells. 47 Thus, PU.1 may be having identical roles in both cell types: inducing transcription and coordinating the interactions between the elements and the CIITA active promoter regions.
The findings that both pI and pIII promoters interact with the same set of cis-elements is intriguing and could have implied that the elements are complex and used different factors to direct the interactions at the specific promoters. However, deletion of pI resulted in the redirection of all interactions to pIII and near wildtype levels of expression. Thus, whereas some transcription factors may be different, the essential properties must be shared. The occurrence of extensive DNA methylation at the pI promoter region in B cells and nearly none in the most 5′ CpGs proximal to the TSS in spDC suggests that pI is epigenetically silenced in B cells. This is supported by previous ChIP data demonstrating a lack of open chromatin (H3 and H4 acetylation) at pI in BCL1 cells. 22 In addition, transcription factor binding or interactions at pIII may be unstable in myeloid cells because of RNA polymerase II transcription from pI through this region of DNA.
In the case of B-cell expression, a similar situation could exist where the critical elements at pI are not accessible, leaving pIII as the only available element for interaction from distal elements and transcription initiation. In B cells, pI is less accessible as measured by DNase I hypersensitivity. 22 In addition, PU.1 occupancy at pIII in B cells is 418 times more than pI, 22 which can be explained by the presence of a lower affinity PU.1-binding motif at pI versus pIII. 27 If PU.1 binding causes or is an indicator of mediating the 3D architecture of the locus, then its preference for pIII could direct expression from this promoter. Together, these data suggest that it is the first or most accessible promoter that is used. This conclusion is consistent with the experiments in which pI was deleted and both looping and transcription were redirected to pIII. Thus, the data presented here identify a host of new elements that contribute to the regulation of CIITA. Whereas some of the elements (for example, PU.1 elements +16 and +19) may simply serve as binding sites for increased accessibility to the local chromatin, other sites have independent regulatory activity and interact directly with CIITA promoters. From a disease perspective, the discovery of novel elements and their potential binding factors could be targets of microbial products aimed at reducing CIITA and MHC-II expression and avoiding immune detection. Intriguingly, one bare lymphocyte syndrome patient who exhibited profoundly reduced levels of CIITA mRNA did not have a mutation in the coding region or at pIII and pIV. 48 The authors suggested that this represented a novel cis-element regulatory defect for CIITA expression. Unfortunately, the mutation was not mapped but provides evidence that the regulatory elements could contribute to MHC-II-associated diseases. The data also demonstrate that several of the elements are shared between cells of the myeloid and lymphoid lineages, implicating additional mechanisms, including DNA methylation and potentially other epigenetic processes as mediators of promoter choice. C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and 6-to 8-week-old mice were used to obtain primary B cells and spDC. For primary B cells, spleens were harvested and a single-cell suspension generated by forcing cells through a 40-μm nylon cell strainer before lysis of the red blood cells using ammonium-chloride potassiumchloride lysis buffer. Splenocytes were incubated with anti-CD43 antibody to deplete non-B cells using MACS columns according to the manufacturer's protocol (Miltenyi Biotech Inc., Auburn, CA, USA).
MATERIALS AND METHODS
SpDC were collected as previously described from wild-type or CIITA promoter I KO mice. 12 Briefly, 30 μg Flt3 Ligand-Ig (Flt3-L) was injected intraperitoneally for 9 days. Flt3-L was provided by Dr R Mittler (Emory University). At the end of 9 days, mice were killed and their spleens were removed and injected with Dulbeco's modified Eagle's media (Mediatech Inc.) containing 10% fetal bovine serum, 1 × non-essential amino acids, 10 mM HEPES, 1 mM sodium pyruvate, 0.292 mg ml − 1 L-glutamine, 100 units ml − 1 penicillin, 100 μg ml − 1 streptomycin (Life Technologies, Grand Island, NY, USA) and 1 mg ml − 1 collagenase D (Roche, Indianapolis, IN, USA). The spleens were then cut into pieces and incubated at 37°C for 25 min. A 40-μM cell strainer was used to generate a single-cell suspension, and ammonium-chloride potassium-chloride lysis buffer was used to lyse red blood cells. CD11c+ dendritic cells were purified using CD11c MACS beads (Miltenyi Biotech Inc.) according to the manufacturer's protocol.
Animal experiments were conducted using protocols that were approved by the Emory University Institutional Animal Care and Use Committee.
Dnase I hypersensitivity assay DNase I hypersensitivity assays were performed as described previously. 49 Briefly, 2 × 10 7 cells were sedimented, resuspended in 1.2 ml ice-cold DNase I buffer (10 mM HEPES, pH 8.0, 50 mM KCl, 5 mM MgCl 2 , 3 mM CaCl 2 , 0.1% NP-40, 8% glycerol and 1 mM dithiothreitol) and incubated on ice for 5 min. Four aliquots of cells in microfuge tubes were placed in a 25°C water bath for 3 min. DNase I (2 U μl − 1 , Worthington, Lakewood, NJ, USA) was added to the samples for 3 min before quenching with 20 mM EGTA. DNase-free RNase A and Proteinase K were then added to the samples and incubated at 65°C overnight. Two microliters of each sample were used for PCR. For real-time PCR analysis, the DNA was purified and quantitated. Relative hypersensitivity was calculated by normalization to an insensitive region within CIITA (Y6) and the data were displayed as fold over the untreated sample. 22 To perform semiquantitative analysis of DNase I-treated samples, conventional PCR was used to amplify 1-2 kilobase (kb) amplicons. The resulting ethidium bromide-stained DNA bands in the agarose gel images were analyzed using iminterp3v2 (S. Edwards, Cincinnati, OH, USA, available upon request). Band intensities were compared with the untreated samples and plotted to obtain a slope to describe the change in intensity with DNase I treatment. As DNase I treatment either results in no change in sensitivity or an increase in sensitivity, only negative slope values were considered for further analysis.
Real-time PCR analysis
Samples were analyzed in 25 μl PCRs containing 1 × SYBR Green I (Lonza Inc., Allendale, NJ, USA) for detection by the CFX96 Real-Time PCR detection system (Bio-Rad Inc., Hercules, CA, USA). Primers used can be found in Supplementary Table 1 . Data represent the average of three independent biological replicates, and error bars represent s.e.m. except where noted. Two-tailed Student's t-tests were used to calculate P-values.
Quantitative 3C assay
The 3C assay protocol was performed as described previously. 25, 26 For primary splenic B cells and dendritic cells, 1 × 10 7 cells were suspended in RPMI with 10% heat-inactivated fetal bovine serum and crosslinked for 10 or 15 min at room temperature with formaldehyde (Sigma-Aldrich) added to cells for a final concentration of 1 or 2% as noted. Glycine (SigmaAldrich) at a final concentration of 125 mM was used to quench the reaction. Digestion was performed overnight on nuclei collected from the crosslinked cells, and digested with either HindIII or EcoRI (New England Biolabs, Ipswich, MA, USA) as indicated at 37°C. Overnight ligations at 16°C with T4 DNA ligase (New England Biolabs) were performed with heatinactivated,~1:40 dilutions of the restriction enzyme-digested reactions. To quantitate 3C products, real-time PCR was performed against a fivepoint standard curve as described previously. 26 Primers (Supplementary  Table 1 ) were tested to determine whether they could amplify a single product on a BAC (RP23-240H17 purchased from Children's Hospital Oakland Research Institute) digested with the appropriate restriction enzyme and re-ligated to form all possible 3C products. Data are presented as crosslinked frequency and represent an average derived from three independent biological replicates with error bars representing s.d. The Student's t-test was used to determine significance.
Luciferase gene reporter assays
Fragments (200-300 bp) were PCR-amplified with primers containing XhoI restriction sites (see Supplementary Table 1 ). These fragments were cloned into the pGL3-promoter vector (Promega Corporation, Madison, WI, USA) using the XhoI restriction site. Inserts were verified by restriction digest followed by DNA sequencing. Supercoiled plasmids were prepared using cesium-chloride gradients. Nucleofection was performed on A20 cells according to Amaxa protocol (Lonza Inc.) using 5 μg of luciferasecontaining pGL3 constructs along with 200 ng of Renilla expression plasmid (pRL-TK, Promega Corporation). After 24 h, cells were harvested and dual-luciferase assays were performed according to the manufacturer's instructions (Promega Corporation). Data were collected in at least triplicate with independent biological replicates, error bars represent s.e.m. and Dunnett's test was used to calculate P-values.
Bisulfite sequencing
Genomic DNA (200 ng) from spDC and B cells was bisulfite-converted using the EZ DNA methylation-gold kit (Zymo Research, Irvine, CA, USA). Bisulfite-converted DNA was PCR-amplified using region-specific primers (Supplementary Table 1 ) and cloned using the TOPO TA cloning kit (Life Technologies). Individual clones were sequenced using an ABI3100 capillary sequencer (Beckman Coulter Inc., Brea, CA, USA). Bisulfiteconverted data were analyzed as previously described. 35 Briefly, this involved mapping the sequence back to the in silico bisulfite-converted genomic DNA sequence using the R Biostrings package. Biological duplicates were performed for all regions. Statistical significance between samples was determined using Fischer's exact test.
